Aston Molecules Ltd., Oncogene deal

ONCS acquired Aston for 284,000 shares of ONCS stock. ONCS, which closed at $8.625 on Friday, has 21.9 million shares outstanding prior to the acquisition.

Aston has been providing medicinal chemistry support to ONCS's drug discovery programs since February 1994, applying its high-speed analog technology to create analogs of ONCS's lead compounds. Aston also has a preclinical service business that provides formulation and drug stability services. ...